TBL1 inhibitor, Tegavivint, for desmoid tumors and hepatocellular carcinoma (2024-02-28)
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Published Date
Publisher
Type
Abstract
David Stenehjem, PharmD, BCOP, Associate Department Head and Associate Professor, Department of Pharmacy and Pharmaceutical Sciences, College of Pharmacy, Duluth
Description
Wednesday, February 28; 3:30 pm; School of Medicine - Room 142 or Zoom
Related to
Replaces
License
Collections
Series/Report Number
Academic Health Center Duluth Research Seminar Series
Funding information
College of Pharmacy; Medical School, Duluth Campus
Isbn identifier
Doi identifier
Previously Published Citation
Other identifiers
Suggested citation
University of Minnesota Duluth. Medical School, Duluth Campus. (2024). TBL1 inhibitor, Tegavivint, for desmoid tumors and hepatocellular carcinoma (2024-02-28). Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/272296.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.